Equity
€2.5m ▲ 25.5%
Advanced Practical Diagnostics has made a profit without a break since 2021.
Advanced Practical Diagnostics
Overview
Lifetime
17 annual accounts with figures on one time axispeak €2.3m (2025)
€2.3m▲ 11.8%
lowest -€1.4m (2012)
€508,322▲ 52.8%
peak €2.5m (2025)
€2.5m▲ 25.5%
€2.0m▼ 9.7%
peak 14.1 FTE (2019)
12.3 FTE▼ 5.4%
Board2 names since 2013
1 directorVerstappen Pascale Louisa Petrus
Owners
Documentsfilings and deeds
17-07-202614 days before the deadline
2025abbreviated format
Result from €332,572 to €508,322Equity from €2.0m to €2.5mCash from €23,065 to €193,629
Key points
from the 2025 annual accountsResult
€508,322 ▲ 52.8%
The result rose in 2025 from €332,572 to €508,322.
Turnover
≈ €3.9m estimated
The abbreviated format states no turnover.
Staff
12 employees on 31-12-2025
In 2025, 2 people joined and 3 left.
Filings
17 annual accounts since 2009
The 2024 accounts came 25 days late. The other nine of the last ten were filed on time.
Position in the sector
€508,322
Higher net result than 95% of companies in pharmaceuticals. Sector median -€11,123 · 62 companies.
Checked score
96
Excellent
Financially stronger than 64% of small companies in pharmaceuticals (NACE 21)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 44 companies (NACE 21, small).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%
01-2025: 0.4%● unchanged vs 12-2024
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.5%▲ +0.1 percentage points vs 05-2025
07-2025: 0.6%▲ +0.1 percentage points vs 06-2025
08-2025: 1.1%▲ +0.5 percentage points vs 07-2025highest value
09-2025: 0.2%▼ -0.9 percentage points vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.3%▲ +0.1 percentage points vs 05-2026
07-2026: 0.3%● unchanged vs 06-2026
08-2026: 0.1%▼ -0.2 percentage points vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026lowest value
10-2026: 0.1%● unchanged vs 09-2026lowest value
11-2026: 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
lowers risk
Founded in 2008
Size: 12.3 FTE, total assets €4.5m
Figures for financial year 2025 (filed on 17-07-2026)
Profit of €508,322 (financial year 2025)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small). It does better than 55% of them on solvency, 50% on liquidity, 80% on profitability and 73% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as Advanced Practical Diagnostics has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
That fits the bankruptcy probability of Advanced Practical Diagnostics itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for Advanced Practical Diagnostics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €240,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.15 (1.62 in 2024), above the usual 1.5. Short-term debt is 26.1% and cash 4.3% of total assets. 44.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
5 signals, none raises the risk
Five signals.
lowers riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 17-07-2026, 14 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
14 days early
2024
25 days late
2023
on the day
2022
18 days early
2021
13 days early
2020
17 days early
2019
2 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 6 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 18 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Capital increase of €1,000,000
7,555 new shares · Change of role: Verstappen Pascale Louisa Petrus, from manager to director · General meeting of 14-12-2020 · Gazette deed
Appointment: Nicolas Karel Jan (successor manager)
General meeting of 16-10-2018 · Gazette deed
First establishment
Raadsherenstraat 3, Turnhout
Incorporation
published on 02-10-2008 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Advanced Practical Diagnostics Turnhout | - | - | 55.5% | 12.3 |
| ASTEL MEDICA Neupré | - | - | 53.2% | 14.6 |
| CRESSANA Zwalm | - | - | 84.1% | 4.4 |
| BIVIT Wevelgem | - | - | 17.8% | 23.5 |
| BETAPLUS PHARMA Woluwe-Saint-Lambert | €5.4m | 23.2% | 89.8% | 11.3 |
| Hyloris Developments Liège | €5.1m | - | 87.1% | 12.2 |
| PHARMACIE SMITS Wavre | - | - | 14.0% | 8.2 |
These companies have the same main activity as Advanced Practical Diagnostics: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €1.9m and €25m, founded between 1989 and 2013.
Official details
Source: KBO- Status
- Active since 18-09-2008Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 2 others
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment unit
- 2.173.180.2782300 Turnhout, since 24-09-2008
- Financial year end
- 31 December
- Peppol
- Reachable
Annual accounts 2025
- €2.3m▲ 11.8%
- €508,322▲ 52.8%
- €2.5m▲ 25.5%
- €4.5m▲ 7.0%
- Employeeson 31-12-2025
- 12▼ 7.7%
- Filing
- Filed on 17-07-2026, 14 days before the end of the filing period
Insights on Advanced Practical Diagnostics
Advanced Practical Diagnostics files the abbreviated format. That format states no turnover. The gross margin rose from -€69,851 in 2009 to €2.3m in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
abbreviated format, filed on 17-07-2026, 14 days before the deadline€2.3m
▲ 11.8%
€618,658
▲ 38.3%
€508,322
▲ 52.8%
€1.3m
▲ 59.9%
55.5%
▲ 8.2 percentage points
2.15
▲ 0.53
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €3.9m. Estimated: probably between €2.7m and €6.5m.
Balance sheet
balance sheet total €4.5m on 31-12-2025What the company ownsHow it is paid for
in €m
in euro
Position in the sector
55.5%
Higher than 70% of 62 companies in 2025.
2.15
Higher than 65% of 61 companies in 2025.
11.3%
Higher than 90% of 61 companies in 2025.
Advanced Practical Diagnostics
Middle half of the sector
80% of the sector
Abbreviated accounts in pharmaceuticals (NACE 21)
Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter · Staff: top quarter
Staff
€101,212
Staff costs divided by the average number of full-time equivalents.
-1 person
people who joined
people who left
In 2025, 2 people joined and 3 left. Training hours in 2025: 64.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||||||||||||||
20/58 |
4.5m | 4.2m | 4.0m | 4.0m | 3.6m | 3.6m | 3.7m | 3.5m | 3.6m | 2.8m | 2.5m | 2.2m | 1.6m | 486,379 | 608,317 | 750,924 | 457,604 | |
21/28 |
2.0m | 2.0m | 2.0m | 2.1m | 1.9m | 1.8m | 1.8m | 1.7m | 1.7m | 1.7m | 1.7m | 1.6m | 1.4m | 228,293 | 521,494 | 522,104 | 327,569 | |
21 |
1.8m | 1.8m | 1.7m | 1.9m | 1.9m | 1.8m | 1.8m | 1.7m | 1.7m | 1.7m | 1.7m | 1.6m | 1.3m | 75,844 | 70,271 | 60,268 | 21,805 | |
22/27 |
134,845 | 200,400 | 209,909 | 201,878 | 17,833 | 17,980 | 23,498 | 7,533 | 3,472 | 4,300 | 12,924 | 25,187 | 100,371 | 152,449 | 189,974 | 233,836 | 77,764 | |
22 |
- | - | - | - | - | - | - | - | - | - | - | - | 24,583 | 26,465 | 30,768 | 35,071 | 23,759 | |
23 |
46,183 | 67,644 | 65,413 | 37,097 | 11,748 | 8,766 | 12,257 | 5,187 | 2,854 | 3,860 | 8,720 | 14,780 | 57,645 | 99,008 | 142,733 | 187,677 | 40,249 | |
24 |
29,980 | 39,725 | 17,115 | 3,050 | 6,084 | 9,214 | 11,241 | 2,346 | 617 | 439 | 4,204 | 10,407 | 18,143 | 26,976 | 16,473 | 11,088 | 13,756 | |
25 |
58,681 | 93,031 | 127,381 | 161,731 | - | - | - | - | - | - | - | - | - | - | - | - | - | |
28 |
1,430 | 1,430 | 1,448 | 1,448 | 1,448 | 1,448 | 1,448 | 1,448 | 1,523 | 1,523 | 1,523 | 1,523 | - | - | 261,250 | 228,000 | 228,000 | |
29/58 |
2.5m | 2.2m | 2.0m | 2.0m | 1.7m | 1.8m | 1.9m | 1.8m | 1.8m | 1.1m | 819,272 | 652,888 | 258,044 | 258,086 | 86,823 | 228,819 | 130,035 | |
3 |
955,387 | 992,597 | 1.0m | 1.0m | 922,051 | 998,285 | 994,554 | 915,961 | 887,083 | 555,582 | 435,964 | 441,843 | 124,949 | 126,350 | 42,773 | 45,849 | - | |
30/36 |
955,387 | 992,597 | 1.0m | 1.0m | 922,051 | 998,285 | 994,554 | 915,961 | 887,083 | 555,582 | 435,964 | 441,843 | 124,949 | 126,350 | 42,773 | 45,849 | - | |
40/41 |
1.3m | 1.2m | 991,052 | 920,895 | 769,481 | 772,568 | 901,623 | 841,714 | 891,255 | 473,120 | 322,355 | 197,815 | 67,600 | 97,870 | 24,599 | 128,223 | 97,291 | |
40 |
762,483 | 857,495 | 906,059 | 858,441 | 769,035 | 772,568 | 901,623 | 841,714 | 891,255 | 473,120 | 319,771 | 190,209 | 66,077 | 75,194 | 23,324 | 126,916 | 60,165 | |
41 |
579,252 | 323,269 | 84,993 | 62,454 | 446 | - | - | - | - | - | 2,585 | 7,606 | 1,523 | 22,676 | 1,276 | 1,307 | 37,126 | |
54/58 |
193,629 | 23,065 | 2,802 | 788 | 824 | 370 | 34,570 | 27,950 | 50,925 | 16,287 | 49,870 | 2,018 | 65,495 | 33,865 | 19,450 | 50,678 | 28,406 | |
490/1 |
34,766 | 13,877 | 10,491 | 11,908 | 2,285 | 2,391 | 10,292 | 14,047 | 11,957 | 6,430 | 11,083 | 11,212 | - | - | - | 4,069 | 4,338 | |
| Balance sheet: equity and liabilities | ||||||||||||||||||
10/49 |
4.5m | 4.2m | 4.0m | 4.0m | 3.6m | 3.6m | 3.7m | 3.5m | 3.6m | 2.8m | 2.5m | 2.2m | 1.6m | 486,379 | 608,317 | 750,924 | 457,604 | |
10/15 |
2.5m | 2.0m | 1.7m | 1.5m | 1.3m | 1.0m | 228,060 | 203,448 | 153,784 | 146,314 | 106,442 | -225,314 | 374,213 | -2.4m | -952,909 | -514,399 | -255,871 | |
10/11 |
1.9m | 1.9m | 1.9m | 1.9m | 1.9m | 1.9m | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 2.8m | 2.8m | 100,000 | 100,000 | 100,000 | 100,000 | |
100 |
- | - | - | - | - | - | 900,000 | 900,000 | 900,000 | 900,000 | 900,000 | 2.8m | 2.8m | 100,000 | 100,000 | 100,000 | 100,000 | |
13 |
601,266 | 92,944 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
133 |
601,266 | 92,944 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
14 |
- | 0 | -239,628 | -387,934 | -575,800 | -872,233 | -671,940 | -696,552 | -746,216 | -753,686 | -793,558 | -3.0m | -2.4m | -2.5m | -1.1m | -614,399 | -355,871 | |
17/49 |
2.0m | 2.2m | 2.3m | 2.5m | 2.3m | 2.5m | 3.5m | 3.3m | 3.4m | 2.6m | 2.4m | 2.5m | 1.3m | 2.9m | 1.6m | 1.3m | 713,475 | |
17 |
826,058 | 851,911 | 876,952 | 1.0m | 924,765 | 929,308 | 1.9m | - | - | - | - | - | - | - | - | - | - | |
170/4 |
826,058 | 851,911 | 876,952 | 1.0m | 924,765 | 929,308 | 1.9m | - | - | - | - | - | - | - | - | - | - | |
42/48 |
1.2m | 1.4m | 1.4m | 1.5m | 1.4m | 1.6m | 1.6m | 3.3m | 3.4m | 2.6m | 2.4m | 2.5m | 1.3m | 2.8m | 1.6m | 1.3m | 712,085 | |
42 |
82,891 | 86,788 | 80,167 | 101,054 | 53,443 | 68,955 | 86,502 | 79,344 | 90,951 | 23,406 | - | 77,067 | - | - | - | - | - | |
43 |
482,042 | 507,131 | 598,959 | 547,814 | 442,530 | 359,880 | 662,547 | 1.1m | 1.1m | 716,772 | 716,772 | 812,355 | 100,000 | - | - | - | - | |
430/8 |
482,042 | 507,131 | 598,959 | 547,814 | 442,530 | 359,880 | 662,547 | 321,813 | 345,845 | - | - | - | - | - | - | - | - | |
439 |
- | - | - | - | - | - | - | 815,772 | 716,772 | 716,772 | 716,772 | 812,355 | 100,000 | - | - | - | - | |
44 |
273,712 | 483,863 | 368,281 | 361,807 | 358,984 | 371,929 | 237,934 | 360,364 | 439,805 | 279,985 | 261,705 | 258,761 | 42,698 | 73,758 | 4,679 | 113,024 | 42,820 | |
440/4 |
273,712 | 483,863 | 368,281 | 361,807 | 358,984 | 371,929 | 237,934 | 360,364 | 439,805 | 279,985 | 261,705 | 258,761 | 42,698 | 73,758 | 4,679 | 113,024 | 42,820 | |
45 |
337,988 | 288,933 | 397,259 | 463,579 | 308,443 | 404,926 | 391,466 | 380,061 | 294,779 | 265,254 | 155,718 | 225,220 | 114,389 | 186,265 | 269,892 | 268,522 | 39,629 | |
450/3 |
184,335 | 147,724 | 204,653 | 261,203 | 135,357 | 196,434 | 228,532 | 175,389 | 138,203 | 93,063 | 46,590 | 79,355 | 29,868 | 7,315 | 148,800 | 132,236 | - | |
454/9 |
153,654 | 141,209 | 192,606 | 202,376 | 173,086 | 208,491 | 162,934 | 204,672 | 156,577 | 172,191 | 109,128 | 145,864 | 84,521 | 178,950 | 121,092 | 136,285 | 39,629 | |
47/48 |
- | - | 0 | 30,945 | 218,573 | 406,994 | 200,145 | 1.4m | 1.5m | 1.3m | 1.3m | 1.1m | 1.0m | 2.6m | 1.3m | 883,537 | 629,636 | |
492/3 |
998 | - | - | - | - | - | 3,926 | - | - | - | - | 4,000 | 1,862 | 12,839 | - | 240 | 1,390 | |
| Income statement | ||||||||||||||||||
76A |
- | - | - | - | - | - | - | - | 6,986 | - | - | - | - | - | - | - | - | |
9900 |
2.3m | 2.0m | 1.9m | 1.9m | 1.7m | 1.1m | 1.5m | 1.5m | 1.4m | 1.3m | 902,485 | 624,162 | 1.2m | -85,048 | 412,832 | 536,472 | -69,851 | |
62 |
1.2m | 1.2m | 1.1m | 1.2m | 939,441 | 940,814 | 1.0m | 1.1m | 1.0m | 946,893 | 874,954 | 926,439 | 990,495 | 923,762 | 725,815 | 688,028 | 243,630 | |
630 |
407,022 | 396,626 | 523,827 | 449,253 | 394,745 | 352,233 | 335,492 | 292,325 | 269,874 | 255,681 | 238,026 | 254,500 | 104,411 | 103,761 | 93,412 | 82,874 | 37,191 | |
631/4 |
3,628 | - | - | - | - | - | - | - | - | - | 165 | - | - | - | - | - | - | |
640/8 |
7,238 | 6,532 | 6,339 | 2,798 | 2,872 | 1,091 | 1,076 | 1,074 | 1,833 | 1,371 | 1,934 | 1,136 | 17,845 | 285,442 | 23,380 | 15,617 | 4,342 | |
66A |
- | - | - | - | - | 0 | 1,781 | 3,324 | 25,000 | -127 | 1 | 14,731 | - | - | - | - | - | |
9901 |
618,658 | 447,183 | 225,003 | 307,153 | 341,537 | -153,920 | 119,453 | 92,761 | 65,734 | 75,238 | -212,594 | -557,913 | 92,404 | -1.4m | -429,774 | -250,047 | -355,014 | |
75/76B |
1,545 | 1,460 | 3,612 | 6,638 | 5,491 | 2,018 | 2,462 | 2,684 | 2,246 | 2,479 | 1,396 | 97 | 317 | 1,555 | 375 | 1,691 | 451 | |
75 |
1,545 | 1,460 | 3,612 | 6,638 | 5,491 | 2,018 | 2,462 | 2,684 | 2,246 | 2,479 | 1,396 | 97 | 317 | 1,555 | 375 | 1,691 | 451 | |
65/66B |
59,243 | 104,868 | 78,436 | 54,667 | 49,293 | 47,053 | 95,941 | 44,506 | 59,114 | 37,309 | 56,458 | 26,236 | 49,302 | 17,533 | 9,110 | 10,172 | 1,309 | |
65 |
59,243 | 104,868 | 78,436 | 54,667 | 49,293 | 47,053 | 95,941 | 44,506 | 59,114 | 37,436 | 56,458 | 26,236 | 49,302 | 17,533 | 9,110 | 10,172 | 1,309 | |
66B |
- | - | - | - | - | - | - | - | - | -127 | - | - | - | - | - | - | - | |
9903 |
560,960 | 343,776 | 150,178 | 259,124 | 297,735 | -198,955 | 25,974 | 50,939 | 8,867 | 40,408 | -267,657 | -598,783 | 43,418 | -1.4m | -438,510 | -258,528 | -355,871 | |
67/77 |
52,638 | 11,204 | 1,872 | 1,400 | 1,302 | 1,337 | 1,362 | 1,274 | 1,398 | 536 | 587 | 743 | 1,258 | 1,048 | - | - | - | |
9904 |
508,322 | 332,572 | 148,306 | 257,724 | 296,433 | -200,292 | 24,612 | 49,665 | 7,469 | 39,873 | -268,244 | -599,527 | 42,160 | -1.4m | -438,510 | -258,528 | -355,871 | |
9905 |
508,322 | 332,572 | 148,306 | 257,724 | 296,433 | -200,292 | 24,612 | 49,665 | 7,469 | 39,873 | -268,244 | -599,527 | 42,160 | -1.4m | -438,510 | -258,528 | -355,871 | |
| Appropriation of the result | ||||||||||||||||||
9906 |
508,322 | 92,944 | -239,628 | -387,934 | -575,800 | -872,233 | -671,940 | -696,552 | -746,216 | -753,686 | -3.3m | -3.0m | -2.4m | -2.5m | -1.1m | -614,399 | -355,871 | |
14P |
0 | -239,628 | -387,934 | -645,658 | -872,233 | - | - | - | - | - | - | - | - | - | - | - | - | |
791/2 |
- | - | - | - | - | - | - | - | - | - | 2.5m | - | - | - | - | - | - | |
691/2 |
508,322 | 92,944 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
6921 |
508,322 | 92,944 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| Social balance sheet | ||||||||||||||||||
9087 |
12.3 | 13 | 13 | 13.2 | 12.8 | 14 | 14.1 | 13.7 | 12.9 | 12.8 | 11 | 10.3 | 10.7 | 11.9 | 10 | 10.9 | 3.5 | |
Hours worked1013 |
20,869 | 21,815 | 21,353 | 23,116 | 22,420 | 23,058 | 24,476 | 24,088 | 21,684 | 20,687 | 18,134 | 17,382 | 17,077 | 19,407 | 17,061 | 18,248 | 6,300 | |
| Document | ||||||||||||||||||
The notes to these accounts have 22 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 17-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 17-07-2026 | 2026-00342288 | |
| 31-12-2024 | abbreviated format | 25-08-2025 | 2025-00407891 | |
| 31-12-2023 | abbreviated format | 31-07-2024 | 2024-00321806 | |
| 31-12-2022 | abbreviated format | 13-07-2023 | 2023-00232672 | |
| 31-12-2021 | abbreviated format | 18-07-2022 | 2022-20201795 | |
| 31-12-2020 | abbreviated format | 14-07-2021 | 2021-35500440 | |
| 31-12-2019 | abbreviated format | 29-07-2020 | 2020-36200029 | |
| 31-12-2018 | abbreviated format | 16-07-2019 | 2019-34000541 | |
| 31-12-2017 | abbreviated format | 23-07-2018 | 2018-36600012 | |
| 31-12-2016 | abbreviated format | 30-05-2017 | 2017-14000165 | |
| 31-12-2015 | abbreviated format | 07-06-2016 | 2016-16200073 | |
| 31-12-2014 | abbreviated format | 23-06-2015 | 2015-21400406 | |
| 31-12-2013 | abbreviated format | 26-06-2014 | 2014-22500512 | |
| 31-12-2012 | abbreviated format | 30-05-2013 | 2013-13800529 | |
| 31-12-2011 | abbreviated format | 20-06-2012 | 2012-18800528 | |
| 31-12-2010 | abbreviated format | 27-05-2011 | 2011-13000004 | |
| 31-12-2009 | abbreviated format | 03-06-2010 | 2010-14900189 |
Subsidies and aid
Flemish government 2022 to 2025, 8 entries, €52,829 awarded, €52,829 paid
| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 4 | €1,078 | €51,078 |
| 2024 | 2 | €51,017 | €1,017 |
| 2023 | 1 | €509 | €509 |
| 2022 | 1 | €225 | €225 |
European Union 5 projects, €1.4m EU contribution
Projects
- Immune Signatures for Therapy Stratification in Major Mood DisordersHorizon 2020, participant, 01-01-2018 to 30-06-2023, €446,500, MOODSTRATIFICATION
- Early diagnosis, treatment and prevention of mood disorders targetting the activated inflammatory response systemSeventh Framework Programme, participant, 01-11-2008 to 30-04-2013, €384,100, MOODINFLAME
- Brain Imaging Return to HealthSeventh Framework Programme, participant, 01-09-2013 to 31-08-2017, €230,340, R'BIRTH
- Advanced Immuno-neuro-endocrine Diagnostics in PsychiatrySeventh Framework Programme, participant, 01-06-2012 to 31-05-2016, €212,433, PSYCH-AID
- European Multicentre Tics in Children StudiesSeventh Framework Programme, participant, 01-12-2011 to 31-05-2017, €144,360, EMTICS
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.0m | 843,809 | 748,830 | 756,406 | 736,282 | 198,313 | 454,944 | 385,086 | 335,608 | 330,920 | 25,432 | -303,414 | 196,815 | -1.3m | -336,363 | -167,173 | -317,823 | ||
| 915,344 | 729,198 | 672,133 | 706,976 | 691,177 | 151,941 | 360,103 | 341,990 | 277,343 | 295,554 | -30,219 | -345,027 | 146,571 | -1.3m | -345,099 | -175,654 | -318,680 | ||
| 385,192 | 436,577 | 417,975 | 650,000 | 534,895 | 345,076 | 393,627 | 315,978 | 290,406 | 284,585 | 330,775 | 471,884 | 1.3m | 71,810 | 92,802 | 277,410 | 364,760 | ||
| 170,564 | 20,263 | 2,014 | -36 | 455 | -34,201 | 6,621 | -22,975 | 34,638 | -33,583 | 47,852 | -63,477 | 31,630 | 14,415 | -31,228 | 22,272 | - | ||
| 1.3m | 843,587 | 575,989 | 471,374 | 312,668 | 160,929 | 362,446 | -1.5m | -1.6m | -1.6m | -1.6m | -1.8m | -1.0m | -2.6m | -1.5m | -1.0m | -582,050 | ||
| 55.5% | 47.3% | 41.7% | 37.4% | 36.5% | 28.8% | 6.1% | 5.7% | 4.3% | 5.3% | 4.3% | -10.1% | 22.7% | -486.9% | -156.6% | -68.5% | -55.9% | ||
| 2.15 | 1.62 | 1.40 | 1.31 | 1.23 | 1.10 | 1.23 | 0.54 | 0.54 | 0.40 | 0.34 | 0.27 | 0.20 | 0.09 | 0.06 | 0.18 | 0.18 | ||
| 1.33 | 0.89 | 0.70 | 0.62 | 0.56 | 0.48 | 0.60 | 0.26 | 0.28 | 0.19 | 0.16 | 0.09 | 0.10 | 0.05 | 0.03 | 0.14 | 0.18 | ||
| 0.80 | 1.11 | 1.40 | 1.67 | 1.74 | 2.47 | 15.42 | 16.42 | 22.17 | 17.81 | 22.41 | - | 3.40 | - | - | - | - | ||
| 20.3% | 16.7% | 8.9% | 17.0% | 22.4% | -19.5% | 10.8% | 24.4% | 4.9% | 27.3% | -252.0% | - | 11.3% | - | - | - | - | ||
| 11.3% | 7.9% | 3.7% | 6.4% | 8.2% | -5.6% | 0.7% | 1.4% | 0.2% | 1.4% | -10.8% | -26.9% | 2.6% | -290.9% | -72.1% | -34.4% | -77.8% | ||
| 17.31 | 8.05 | 9.55 | 13.84 | 14.94 | - | - | - | - | - | - | - | - | - | - | - | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 12 | 13 | 14 | 13 | 13 |
| full-time | 10 | 11 | 12 | 11 | 12 |
| part-time | 2 | 2 | 2 | 2 | 1 |
| in full-time equivalents | 11.7 | 12.6 | 13.6 | 12.6 | 12.8 |
| 12.3 | 13 | 13 | 13.2 | 12.8 | |
| On a permanent contract | 12 | 13 | 14 | 13 | 13 |
| Joined | 2 | 2 | 2 | 3 | 2 |
| Left | 3 | 3 | 2 | 3 | 4 |
| Training hours | 64 | 44 | - | - | - |
Source: social balance sheet in the 2021 to 2025 annual accounts
Securities and guarantees
on own assets and for others| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Debts secured on the company's own assets | €754,858 | €754,858 | €754,858 | €758,370 | - |
| €308,000 | €308,000 | €308,000 | €308,000 | - | |
| Mandates to pledge the business | €89,925 | €89,925 | €89,925 | €89,925 | - |
Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | - | €51,297 | €62,922 | €204,396 | €8,359 |
| Intangible fixed assets | €385,192 | €385,280 | €355,054 | €445,604 | €526,536 |
| Financial fixed assets | €0 | - | - | - | - |
| €407,022 | €396,626 | €523,827 | €449,253 | €394,745 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Public contracts
10 awards · 2023
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Show 5 more contracts
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Levering en installatie van laboratorium toestellen voor de inrichting van een AAV gentherapie platform: automatische ELISA
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. The values are as the buyer published them. For a framework agreement, the value is a ceiling.
Insights on Advanced Practical Diagnostics
The operating result for 2025 is 38% higher than in 2024 and the highest since 2009. It is the second rise in a row, after the fall in 2023.
Debt's share of the balance-sheet total falls from 52.7% to 44.5%. Equity is higher and debt is lower.
Board & ownership
Board
1 director, last change in 2020Director
appointed by deed of 23-12-2020
earlier manager, until 23-12-2020
listed in the 2025 annual accounts, filed on 17-07-2026
Mandates through the years
2 names, the dashed line is todayVerstappen Pascale Louisa Petrus
Director
Director
Nicolas Karel Jan
Successor manager
Successor manager
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
- Verstappen Pascale Louisa Petrus
- Director, from 05-04-2013 to date
- Manager, until 23-12-2020
- Nicolas Karel Jan
- Successor manager, appointed by deed of 31-10-2018, no longer listed in the 2025 annual accounts
Control
Shareholder
Equity €1.7m
Profit €81,801 in 2025 (profit €3,534 in 2024)
Checked score 95
Source: accounts HOVE 2024
3%
This company
Advanced Practical Diagnostics
Equity €2.5m
Profit €508,322 in 2025
Capital
- Contribution
- €1,900,000
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
Source: lists of holdings in the owners' accounts
Articles of association
deed of 23-12-2020 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Indien alle aandelen ingeschreven op naam van één aandeelhouder kan deze vrij beslissen over overdracht alle of deel van zijn aandelen”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- First Saturday of May at 16:30
Capital transactions
Capital over time
- 23-12-2020 Converted to unavailable equity · €900,000
- 23-12-2020 Capital increase of €1,000,000 · 7,555 new shares
Network & group
Holdings
own 2012 accountsThis companyAdvanced Practical Diagnostics1 holding, 1 country
2012 accounts
Belgium 1 Equity Result
- BE Arcom Scientific BVBA32% €127,062 result €4,987
Source: list of holdings in its own 2012 accounts. Every holding stands with its own latest accounts.
At the same address
Raadsherenstraat 3, 2300 Turnhout · 3 other companies| HOVE
registered office since 03-09-1996 · founded in 1996 |
total assets €2.6m (2025) 0458.713.691 |
| Pave
registered office since 25-05-2021 · founded in 2021 |
total assets €191,031 (2025) 0768.708.469 |
| Caelus Lifesciences Belgium
registered office since 24-06-2025 |
founded in 2025 1024.636.041 |
Holdings through the years
2009 to 2012Connections & network
1 current directorThe network starts from the directors of Advanced Practical Diagnostics. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Timeline
30 events since 2008Board
Capital
Filings
Financial
Establishments
2008201020122014201620182020202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBabbreviated format · 14 days before the deadline
2025
Highest result from 2009 to 2025 net €508,322 ▲52.8% The operating result of €618,658 and the net result of €508,322 are both a record.
Equity above €2m equity €2.5m ▲25.5% After 5 profitable years in a row, equity reaches €2.5m.
Annual accounts 2024 filed PDFabbreviated format · 25 days late
2024
Annual accounts 2023 filed PDFabbreviated format · on the deadline day
2023
Annual accounts 2022 filed PDFabbreviated format · 18 days before the deadline
2022
Annual accounts 2021 filed PDFabbreviated format · 13 days before the deadline
2021
Back to profit net €296,433 The net result is €296,433, after one loss-making year.
Annual accounts 2020 filed PDFabbreviated format · 17 days before the deadline
2020
Equity above €1m equity €1.0m ▲351% Equity rises from €228,060 to €1.0m.
Capital increase of €1,000,0007,555 new shares · Change of role: Verstappen Pascale Louisa Petrus, from manager to director · General meeting of 14-12-20204 points ▸
- General meeting, 14-12-2020
- Director resignation, Verstappen Pascale Louisa Petrus (manager)
- Director appointment, Verstappen Pascale Louisa Petrus
- Capital increase, €1,000,000
- The deed holds 3 more points.
Annual accounts 2019 filed PDFabbreviated format · 2 days before the deadline
2019
Liquidity more than doubled current ratio 1.23 The current ratio rises from 0.54 to 1.23. Short-term debt falls from €3.3m to €1.6m.
Annual accounts 2018 filed PDFabbreviated format · 15 days before the deadline
2018
- General meeting, 16-10-2018
- Director appointment, Nicolas Karel Jan (successor manager)
- Amendment of the articles, article 7.1
Annual accounts 2017 filed PDFabbreviated format · 8 days before the deadline
2017
Annual accounts 2016 filed PDFabbreviated format · 62 days before the deadline
2016
Back to profit net €39,873 The net result is €39,873, after 2 loss-making years.
Annual accounts 2015 filed PDFabbreviated format · 54 days before the deadline
2015
Annual accounts 2014 filed PDFabbreviated format · 38 days before the deadline
2014
Annual accounts 2013 filed PDFabbreviated format · 35 days before the deadline
2013
Back to profit net €42,160 The net result is €42,160, after 4 loss-making years.
Equity above €200,000 equity €374,213 Equity rises from -€2.4m to €374,213.
Annual accounts 2012 filed PDFabbreviated format · 62 days before the deadline
2012
Weakest financial year net -€1.4m The net result drops to -€1.4m, the lowest from 2009 to 2025. It recovers the following year.
Annual accounts 2011 filed PDFabbreviated format · 41 days before the deadline
2011
Annual accounts 2010 filed PDFabbreviated format · 65 days before the deadline
2010
Annual accounts 2009 filed PDFabbreviated format · 58 days before the deadline
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 0806.556.285
- VAT number
- BE 0806.556.285
- Peppol ID
- 0208:0806556285
- Other Peppol ID
- 9925:BE0806556285
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 18-09-2008
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- First Saturday of May at 16:30deed of 23-12-2020 (in Dutch)
- Peppol
- Reachable via PeppolFollow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- Advanced Practical Diagnostics in Dutch
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 23-12-2020 (in Dutch)
- Name clauseThe company operates under this name according to its articles.
- Advanced Practical Diagnosticsdeed of 23-12-2020 (in Dutch)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”deed of 23-12-2020 (in Dutch)
Activities
NACEBEL 2025VAT activities
21201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
Social security (RSZ) activities
46460
Wholesale of pharmaceutical and medical goods main activity
Joint committees annual accounts 2025
JC 207
White-collar workers in the chemical industry
Codes under NACEBEL 2008
VAT activities
21201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
32500
Manufacture of medical and dental instruments and supplies
46460
Wholesale trade
Social security (RSZ) activities
46460
Wholesale trade main activity
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Alle activiteiten die verband houden met het ontwikkelen,het produceren,het commercialiseren van farmaceutische,diagnostische of aanverwante…”deed of 23-12-2020 (in Dutch)
2 activities
- Alle activiteiten die verband houden met het ontwikkelen,het produceren,het commercialiseren van farmaceutische,diagnostische of aanverwante producten en van hospitaal en laboratoriumbenodigdheden,alsook de handel in alle gezegde producten en benodigdheden
- Het vervaardigen of laten vervaardigen en het uitvoeren van alle voormelde producten,materialen en materieel
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Raadsherenstraat 3 registered office 2300 Turnhout 2059034 Manufacture of chemicals and chemical products | 24-09-2008 | 2.173.180.278 |
Buildings and parcels at the address
- Ground area
- 1.9 ha
- Buildings
- 4,569 m²
- Volume, LiDAR
- 21,456 m³
- Tallest building
- 33.0 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 13453O0952/00E000 | 1.9 ha | 1 · 4,569 m² | 33.0 m · 2 |